To summarize the recent developments in endocrine disorders associated with Down syndrome.
INTRODUCTION
Down syndrome is the most common chromosomal condition, affecting one in every 787 liveborn babies [1, 2] . This translates to around 5000 babies with Down syndrome born annually in the United States [2] . Down syndrome is associated with intellectual disability as well as medical issues ranging from congenital heart disease, obstructive sleep apnea, celiac disease, to endocrinopathies [3] . Endocrine disorders such as thyroid dysfunction, low bone mass, diabetes, short stature, infertility, and propensity to be overweight/obese are much more common than the typical population [4] . Accurate diagnostics and effective treatments for these conditions do exist; however, best practices for many of these endocrine conditions have not yet been established.
Recent research provides further understanding about the pathophysiology and management of endocrine disorders that without treatment can impact health and development. As life expectancy for individuals with Down syndrome has significantly improved, with a median age of 4 years in the 1950s to 58 years as of 2010 [1] , the medical community is challenged with continuing to optimize our medical treatments to reduce morbidity and maximize function. The following article will review the most current advances, areas of debate, and provide a thoughtful expert opinion on how best to care for patients with Down syndrome.
]. Importance of evaluating vBMD or BMAD is highlighted in several studies when differences in aBMD between patients with Down syndrome and controls were not sustained when comparing vBMD or BMAD [ Bone mineralization is dependent on calcium status. Similar concentrations of serum calcium and phosphorus are seen in people with Down syndrome compared with controls [6, 12, 14] . Adult studies have found similar concentrations of parathyroid hormone (PTH) in patients with Down syndrome and controls [5 & ,12] , whereas studies in children have found higher levels of PTH in children with Down syndrome [14] . Vitamin D deficiency is prevalent in those with Down syndrome, but may only be slightly more common than in the general population [14] .
KEY POINTS
Specific causes of decreased bone mineral density in this population is an area of active research.
Puberty develops typically in individuals with Down syndrome, and fertility is possible.
Thyroid dysfunction is common in individuals with Down syndrome. Controversy remains regarding treatment of subclinical hypothyroidism given unclear benefits.
Risk of several autoimmune conditions is increased in Down syndrome, possibly be due to altered expression of AIRE gene.
Down-syndrome-specific growth charts were published in 2015. See: http://peditools.org/. Various interventions have attempted to improve BMD in this high-risk population, including weight-bearing exercise, plyometrics, and whole-body vibration training [15] [16] [17] [18] ; all improved BMD in individuals with Down syndrome. Adding calcium and vitamin D supplementation to an exercise program lead to greater improvement in BMD than either nutritional or activity intervention alone [15] . Therefore, children with Down syndrome may require higher vitamin D supplementation [12, 13] than the recommended dietary allowance of 400 IU daily.
Pharmacologic interventions to improve BMD in humans include bisphosphonates and intermittent PTH. Ts65Dn mice receiving intermittent PTH therapy improved trabecular microarchitecture and thickness and increased number of osteoblasts on bone surface [11] . Fowler argues that bisphosphonates, which typically decrease bone turnover, would not be beneficial in patients with Down syndrome, as their research showed decreased bone formation at baseline [11] .
With increasing life expectancy, bone health in patients with Down syndrome is an area of growing importance. DXA results of BMD should take into account the height of the patient. Differences in BMD can be seen early in life and worsen with aging. Structured activity and dietary supplementation can improve bone health. More research is needed to determine the specific mechanism of low BMD in this population as well as their fracture risk prior to recommending pharmacologic interventions.
PUBERTY/FERTILITY
Early studies found adults with Down syndrome had higher levels of follicle stimulating hormone and/or luteinizing hormone, consistent with hypergonadotropic hypogonadism [12, 19] . Despite elevated gonadotropins, actual concentrations of sex hormones were similar to controls [12, 19, 20] . The current leading theory is that hypergonadotropic hypogonadism is present in infancy, progresses throughout late puberty to adulthood [20, 21] , and is due to both Sertoli and Leydig cell dysfunction in men [20] . Despite gonadal dysfunction, puberty in patients with Down syndrome can be expected to occur on time and progress at a typical rate [21] [22] [23] [24] [25] . Caregivers should be counseled on this, so they can prepare children with Down syndrome for upcoming pubertal changes. Although hypogonadism is common, infertility should not be assumed. Both men and women with Down syndrome have fathered/mothered children [22, 23, 26, 27] , highlighting the need to have an open discussion with adolescents and adults with Down syndrome about sexuality and parenthood.
THYROID
Individuals with Down syndrome have higher rates of thyroid dysfunction. Abnormalities include subclinical hypothyroidism (SCH; also referred to as hyperthyrotropinemia), congenital hypothyroidism, and thyroid autoimmunity such as Hashimoto's disease or Grave's disease. The American Academy of Pediatrics recommends thyroid screening to be performed at birth, 6 months, and then annually beginning at 1 year old, with increased frequency in SCH [3] . Despite these recommendations, up to 25% of those of more than 1 year do not receive recommended screening [28 & ]. Recent research regarding thyroid disease in Down syndrome has further defined the natural history of thyroid disease and delineated the pathophysiology of SCH and autoimmune thyroid disease in this population.
To characterize the course of thyroid disease in Down syndrome, Pierce et al. [29 && ] performed a large retrospective study of patients with Down syndrome and found a similar prevalence, with 24% of patients affected and SCH as the most common diagnosis. Patients with Down syndrome also had a higher prevalence of congenital hypothyroidism with some cases identified on thyroid tests performed within the first 6 months of life that were not picked up on newborn screening. A recent retrospective study of 159 neonates with Down syndrome raises concern that T4-based newborn screening may miss many cases of congenital hypothyroidism [30] . Based on these findings, Pierce et al. recommend increased screening frequency less than 6 months of age. Although the risk of thyroid abnormalities increased 10% yearly, 13% of patients had transient dysfunction [29 && ]. Previous research supports this finding, as SCH is not a precursor to definite hypothyroidism [31] . Among both congenital hypothyroidism and SCH patients, trials off levothyroxine may be considered if TSH elevation remains mild (<10) and no dose escalations were required after initiating therapy.
In addressing the high frequency of TSH elevation among individuals with Down syndrome, Meyerovitch et al. [32] analyzed the distribution of TSH and FT4 levels compared with age-matched and sex-matched controls. A significant upward shift of the curve was present for TSH among patients with Down syndrome, with the 2.5-97.5 percentile ranging 1.3-13.1 compared with 0.4-6.6 mIU/l in controls. They argue that this is not due to SCH, but rather to a resetting of the hypothalamic-pituitary-thyroid (HPT) axis. Based on this, Meyerovitch et al. recommend treating SCH only if TSH remains more than 95th percentile (>9 mIU/l based on their data). This recommendation is consistent with recent literature regarding children without Down syndrome, in whom TSH elevation may be transient and treatment is recommended if clinical symptoms or TSH elevation more than 10 mIU/l persists [33] .
The clinical significance of SCH and whether it warrants treatment has been debated and few RCTs to date have evaluated early treatment. Van Trostenburg et al. performed a single-center, double-blinded, randomized controlled trial of early treatment with Levothyroxine among a sample of 224 neonates with Down syndrome. They reported mild improvements in motor development and height in treated infants compared with controls at 2 years [34] ; however, follow-up at 10 years of age found no developmental differences between groups [35] . Zwaveling-Soonawala et al. [36 && ] recently evaluated the effect of early treatment on thyroid function at 10 years of age within this cohort. They found that early treatment with levothyroxine was associated with a mild increase in FT4 level; however, no change in TSH level compared with controls, potentially representing a 'resetting' of the HPT axis set-point. In addition, there was less autoimmune thyroid disease in the treated group, suggesting a potential protective role for early levothyroxine treatment.
Patients with Down syndrome with TSH more than 10 mIU/l are more likely to have evidence of thyroid autoimmunity [29 && ] and more likely to progress to overt hypothyroidism in the setting of positive thyroid antibodies [37] . In a multicenter retrospective trial, Aversa et al. [38] found that autoimmune thyroid disease in Down syndrome has less female predominance, a lower age at diagnosis, less family history of thyroid disease, and increased association with other autoimmune diseases compared with the general population. Hashimoto's thyroiditis (HT) converts to Grave's disease more frequently in Down syndrome compared with the general population [39] . In a retrospective study of patients with Down syndrome who transitioned from HT to Grave's disease, the majority had SCH at diagnosis. The course was overall mild, with clinical stability on low-dose methimazole, no need for definitive treatment, and some patients experiencing remission [40] .
AUTOIMMUNITY AND TYPE 1 DIABETES
Beyond autoimmune thyroid disease, individuals with Down syndrome carry an overall increased risk of autoimmunity. Among a population of children with autoimmune thyroid disease, Aversa et al. [41] found that children with Down syndrome had higher rates of extrathyroidal autoimmune compared with children without Down syndrome. Most common autoimmune diagnoses were alopecia areata, vitiligo, and celiac disease.
There is also an increased risk of type 1 diabetes (T1D) in individuals with Down syndrome that is often diagnosed earlier in life compared with individuals without Down syndrome. As a result, debate exists regarding the mechanism of T1D in Down syndrome. Butler et al. [42] found no difference in pancreatic fractional beta cell area in those with Down syndrome compared with those without. Two recent studies found increased rates of diabetes-associated auto-antibodies in individuals with Down syndrome compared with the typical population without the expected increase in diabetes-associated human leukocyte antigen genotypes [43, 44] . Abnormal expression of the AIRE gene, located on chromosome 21 (21q22.3 region) has recently been identified as a likely cause for increased autoimmunity in Down syndrome. As the AIRE gene regulates T-cell function and self-recognition, dysfunction may result in autoimmunity. Recent research confirms abnormal AIRE expression within children with Down syndrome, with Skogberg et al. [45] finding increased expression in infants and Gimenez-Barcons et al. [46] finding decreased AIRE expression in older children. These results suggest that abnormal AIRE expression on chromosome 21 may have important implications for autoimmunity in Down syndrome, although more research is needed.
GROWTH AND OBESITY
The first Down-syndrome-specific growth charts in the United States were published in 1988 [47] , as children with Down syndrome have different growth rates compared with typically developing children. These initial growth charts noted delayed linear growth and increased overweight. With medical advances, concern arose that these initial growth charts no longer represented the current population of individuals with Down syndrome. Updated growth charts reflecting a cohort of US children with Down syndrome were released in 2015 which revealed significant improvement in weight status for children less than 36 months of age, who were previously underweight [48] . Although males 2-20 years old were taller overall than previous charts, this effect did not exist for women. Despite the increasing childhood obesity in the United States over this time as well as the known increased prevalence of overweight within the population with Down syndrome, there were similar rates of overweight compared with the 1988 growth charts.
With regard to BMI, however, the Down syndrome-specific charts must be interpreted with caution due to the increased prevalence of obesity among individuals with Down syndrome [49] . Compared with typically developing children with the same BMI, body composition analysis with DXA scans shows that children with Down syndrome have lower lean mass index and higher fat mass index [50 && ]. As a result, although the Down syndrome BMI charts are ideal for comparison with peers, the Centers for Disease Control and Prevention (CDC) 2000 growth chart and its 85th percentile BMI should be used to identify excess adiposity in children with Down syndrome.
CONCLUSION
Down syndrome is the most common chromosomal condition. Pathophysiology of bone health in this disorder is an area of active research and of growing importance as life expectancy increases. The belief that these patients are infertile is untrue, and they experience puberty at a similar rate/tempo as other children. Autoimmune disease, particularly thyroid disease, is prevalent, and new research is focusing on the underlying genetic cause of autoimmunity. Obesity remains common, as does short stature, with new growth curves available for reference.
